We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
Read MoreHide Full Article
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare announced that the FDA has granted approval to a new once-daily, single-tablet two-drug regimen (2DR), Dovato for the treatment of newly-diagnosed adults with HIV-1 infection.
Dovato is a fixed-dose combination of Glaxo’s successful HIV drug Tivicay(dolutegravir- 50 mg) in combination with lamivudine (300 mg). The submission is based on the global GEMINI 1 & 2 studies that evaluated the two-drug regimen in treatment naïve HIV patients who have not received prior antiviral therapy compared to a three-drug regimen of dolutegravir plus tenofovir alafenamide fumarate and emtricitabine. The new drug application (NDA) for this single-tablet regimen was filed in October last year using a priority review voucher.
At week 48, the studies demonstrated that the dolutegravir and lamivudine regimen was non-inferior to the standard three-drug regimen. This means a two-drug HIV regimen can control HIV in treatment naïve patients as effectively as a three-drug regimen, thereby exposing these newly diagnosed patients to fewer drugs at the start of treatment. A similar application is under review in the EU.
ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer (PFE - Free Report) . It markets another two-drug, once-daily, single pill for HIV, Juluca, which is a combination of Tivicay and J&J’s (JNJ - Free Report) Edurant (rilpivirine). Juluca was approved in the United States in late 2017 and in the EU in mid-2018 for HIV patients that have received prior treatment.
So far this year, Glaxo’s shares have outperformed the industry, rising 9.1% compared with 3.6% increase for the industry.
HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, Tivicay, Triumeq and Juluca in its portfolio. HIV sales totaled £4.7 billion in 2018 with dolutegravir-based regimens generating £4.4 billion driven by increased market share.
ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralising antibodies). Key candidates in late-stage development include a long-acting, injectable two-drug regimen of cabotegravir and rilpivirine and fostemsavir in heavily pre-treated HIVpatients. New drug applications for both these candidates are expected to be filed this year.
Other key players in the HIV market are Gilead (GILD - Free Report) , Merck, AbbVie and J&J.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare announced that the FDA has granted approval to a new once-daily, single-tablet two-drug regimen (2DR), Dovato for the treatment of newly-diagnosed adults with HIV-1 infection.
Dovato is a fixed-dose combination of Glaxo’s successful HIV drug Tivicay(dolutegravir- 50 mg) in combination with lamivudine (300 mg). The submission is based on the global GEMINI 1 & 2 studies that evaluated the two-drug regimen in treatment naïve HIV patients who have not received prior antiviral therapy compared to a three-drug regimen of dolutegravir plus tenofovir alafenamide fumarate and emtricitabine. The new drug application (NDA) for this single-tablet regimen was filed in October last year using a priority review voucher.
At week 48, the studies demonstrated that the dolutegravir and lamivudine regimen was non-inferior to the standard three-drug regimen. This means a two-drug HIV regimen can control HIV in treatment naïve patients as effectively as a three-drug regimen, thereby exposing these newly diagnosed patients to fewer drugs at the start of treatment. A similar application is under review in the EU.
ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer (PFE - Free Report) . It markets another two-drug, once-daily, single pill for HIV, Juluca, which is a combination of Tivicay and J&J’s (JNJ - Free Report) Edurant (rilpivirine). Juluca was approved in the United States in late 2017 and in the EU in mid-2018 for HIV patients that have received prior treatment.
So far this year, Glaxo’s shares have outperformed the industry, rising 9.1% compared with 3.6% increase for the industry.
HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, Tivicay, Triumeq and Juluca in its portfolio. HIV sales totaled £4.7 billion in 2018 with dolutegravir-based regimens generating £4.4 billion driven by increased market share.
ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralising antibodies). Key candidates in late-stage development include a long-acting, injectable two-drug regimen of cabotegravir and rilpivirine and fostemsavir in heavily pre-treated HIVpatients. New drug applications for both these candidates are expected to be filed this year.
Other key players in the HIV market are Gilead (GILD - Free Report) , Merck, AbbVie and J&J.
Glaxo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>